Introduction
Adult intracranial subdural myeloid sarcoma with an acute deterioration has been documented in the context of acute myeloid leukaemia (AML). 1 Myeloid sarcoma in general is, however, more common in the paediatric population and in those with certain genetic abnormalities. 2 Intracranial myeloid sarcoma more commonly presents as an intra-axial 3 lesion or an extra-axial intra-dural lesion. [4] [5] [6] Myeloid sarcoma has also been documented to present outside the context of AML 7 and in those who have had successful treatment of their AML and are in complete remission. 8 This paper presents the first documented subdural intracranial myeloid sarcoma with an acute deterioration in the context of AML thought to be in remission. This case underlines the critical importance of timely contrastenhanced cranial imaging of a deteriorating patient who has a suspected diagnosis or with a past medical history of leukaemia.
Case report
A 74-year-old male presented to hospital for consolidation chemotherapy with a one-week history of headache on a background persistent thrombocytopaenia following induction chemotherapy for acute myeloid leukaemia (AML) of French-American-British (FAB)-M5 subtype. The AML developed from chronic myelomonocytic leukaemia diagnosed three years previously and had been in complete remission for six weeks at the date of admission. The patient deteriorated within 24 hours, becoming confused and drowsy. A non-contrast computed tomography (CT) (Figure 1(a) ) revealed an extensive right-sided, mildly hyper-dense subdural collection measuring 17 mm at maximal depth with 10 mm of midline shift and oedema in the underlying white matter of the right fronto-parietal regions, including the left frontal lobe. Limited magnetic resonance imaging (MRI) compromised by movement, revealed an isointense lesion in the right subdural space on T1-and T2-weighted imaging with a margin of more pronounced low signal on T2 (Figure 1(d) ) and diffusion consistent with blood product (Figure 1(b) , (c)).
Blood results at admission revealed a thrombocytopaenia of 27 Â 10 9 /l (150-400) and a white cell count of 3.5 Â 10 9 /l (3.5-10.0). The majority of these were mature neutrophils and there were no blasts. Platelets were transfused prior to surgical decompression and on exposure of the subdural space during surgery, a solid tumour-like substance was identified and debulked. On the third postoperative day the patient passed away after palliative care referral. 
Discussion
With an incidence of 18%-24% in those with 11q23/ myeloid-lymphoid leukaemia rearrangements on bone marrow cells or a t(8;21) translocation, myeloid sarcoma is an otherwise rare intracranial finding. 2, 9 Myeloid sarcoma has been described as isointense to the brain on T1 and T2 imaging as confirmed by the postoperative images in Figure 2 (a) and (b). 10 Intraaxial myeloid sarcoma can be hypodense, cystic, have necrotic cores or present like abscesses. 6 The diagnosis of tumour would be more likely than a diagnosis of 
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The Neuroradiology Journal 30 (3) haemorrhage in the neurologically deteriorating patient with contrast imaging if the content of the subdural mass enhanced homogeneously. Lobulated contour and multi-focality also argue towards a diagnosis of tumour rather than haemorrhage, features that can be hard to discern without contrast enhancement. 1, 11, 12 The diagnosis of myeloid sarcoma is suggested by the above radiological features, the clinical context and the position of the mass in the absence of any bony disease.
Postoperative MRI under anaesthesia and with contrast (Figure 3 (a)-(c) and Figure 4 (a)) showed diffuse intense enhancement of the content of the residual subdural lesion post-evacuation, in addition to other nodular foci of subdural enhancement over both hemispheres as seen in Figure 3 .
It is of note that there was no imaging evidence of bone marrow involvement in the skull or upper cervical region to indicate a path of invasion through the dura as can be seen in Figure 3 (c). 13 There was evidence of haemosiderin at the margins of the subdural collection on susceptibility-weighted imaging (SWI) ( Figure 4(b) ), in keeping with the presence of blood product. Figure 5 demonstrates the histopathology confirming myeloid sarcoma. The term 'chloroma' comes from the green colour that is sometimes encountered but is a term less commonly used than 'myeloid sarcoma'. 14 A myeloperoxidase stain was negative in this tumour (not shown). Immunohistochemistry for CD68 ( Figure 5(b) ) and CD43 (not shown) were positive, however, confirming monocytic lineage.
Treatment of myeloid sarcoma can include intrathecal or intravenous chemotherapy, radiation therapy and surgical resection. 2, 5 It is still unclear as to whether in those with t(8;21) translocations, early aggressive therapy should be considered, such as bone marrow transplantation. 9
Differential diagnoses
. Subdural haemorrhage -Marginal rather than solid enhancement . 
Conclusion
In the radiological diagnosis of intracranial lesions, always consider myeloid sarcoma in the differential for patients with a past medical history of leukaemia. When obtaining cranial CT or MRI in these patients, always use contrast or gadolinium. In the deteriorating patient, imaging with contrast should be obtained in a timely fashion. Nodular, homogeneously enhancing, multi-focal lesions without bony invasion in a patient with a history of leukaemia would make a diagnosis of myeloid sarcoma highly likely. 
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